Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

[1]  G. Raju,et al.  Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis , 2018, Journal of Immunotherapy for Cancer.

[2]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[3]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[4]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[5]  Mark M. Davis,et al.  Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade , 2017, Proceedings of the National Academy of Sciences.

[6]  A. Bäumler,et al.  Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. , 2017, Current opinion in microbiology.

[7]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Lauwers,et al.  Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies , 2017, The American journal of surgical pathology.

[9]  R. Bresalier,et al.  Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors , 2017, Current Gastroenterology Reports.

[10]  Ben Nichols,et al.  VSEARCH: a versatile open source tool for metagenomics , 2016, PeerJ.

[11]  A. Diab,et al.  Managing Adverse Events With Immune Checkpoint Agents , 2016, Cancer journal.

[12]  C. Huttenhower,et al.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.

[13]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[14]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[15]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.

[16]  J. Wolchok,et al.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Taur,et al.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[19]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[20]  William A. Walters,et al.  Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms , 2012, The ISME Journal.

[21]  T. Borody,et al.  Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.

[22]  R. Knight,et al.  UniFrac: an effective distance metric for microbial community comparison , 2011, The ISME Journal.

[23]  Michael A McGuckin,et al.  Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of Mucin by Other Bacteria , 2010, The American Journal of Gastroenterology.

[24]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[25]  J. Barkin,et al.  Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab , 2009, Digestive Diseases and Sciences.

[26]  David J Van Horn,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[27]  M. Kashani-Sabet,et al.  Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. , 2009, Cancer biotherapy & radiopharmaceuticals.

[28]  B. Flourié,et al.  CD8+ cytotoxic T cells induce relapsing colitis in normal mice. , 2006, Gastroenterology.

[29]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Kappeler,et al.  The role of activated cytotoxic T cells in inflammatory bowel disease. , 2000, Histology and histopathology.